Contact Us v2
"*" indicates required fields
The structural complexity and sensitivity of biologics demand a specialized analytical approach. As development timelines tighten and regulatory expectations remain high, many manufacturers look to external partners for biologics testing services that are both technically rigorous and responsive to evolving needs.
BA Sciences offers comprehensive biologics analytical services to support regulatory submissions and ongoing product quality. Our testing programs are designed to meet FDA and EMA expectations and to help accelerate progress toward clinical trials and commercialization.
Our biologics analytical development team works with a wide range of biologic drug formats, including monoclonal antibodies, recombinant proteins, and biosimilars. We provide method development, validation, and cGMP-compliant testing with a focus on accuracy, reproducibility, and regulatory alignment.
Our testing services support:
We use platform-specific assays tailored to protein-based drugs, including but not limited to:
Testing methods must reflect the differences between biologics and small molecule drugs. Protein-based therapeutics require analytical techniques that account for their size, folding, and post-translational modifications. A pharmaceutical biologics testing partner must be able to navigate these requirements and apply suitable methods to assess structural integrity and product consistency.
For additional information on this distinction, see our blog on the
difference between biologics and small molecule stability testing.
Biologics testing is a dedicated function within our lab. The team brings direct experience with protein-based drugs and applies methods aligned with regulatory expectations from early development through commercial release.
What we provide:
Our biologics analytical services are structured to meet technical requirements while helping clients maintain project momentum.
"*" indicates required fields